Ipsen’s latest R&D alliance brings novel T cell-activating drugs for cancer
Ipsen has been an active dealmaker lately, and it just struck another one that takes the pharmaceutical company into a new area of drug research. […]
Ipsen has been an active dealmaker lately, and it just struck another one that takes the pharmaceutical company into a new area of drug research. […]
Are you using TCRs to target solid tumors yet? With Immunocore having achieved commercialization for the first TCR therapy in both the US and EU […]
Immunocore now has approval on both side of the Atlantic for Kimmtrak – the first cancer therapeutic based on T cell receptor (TCR) technology – […]
Affini-T Therapeutics is developing new cell therapies for cancer that could overcome limitations of the first generation of cell therapies. The initial genomic cancer targets […]
Bayer’s venture capital unit has co-led a $175 million investment in Affini-T that will be used to take its T cell receptor (TCR) therapies for […]
Immunocore has secured a piece of biotech industry history, becoming the first company to get an FDA approval for a cancer therapeutic based on T […]
The 2nd TCR-based Therapies Summit is the leading industry-focused meeting dedicated to supercharging the expanded TCR repertoire through enhanced target specificity, density and binding affinity for solid […]
Copyright © 2024 | WordPress Theme by MH Themes